Adamas to Present at Upcoming William Blair Conference
Rhea-AI Summary
Adamas Pharmaceuticals (Nasdaq: ADMS) announced that CEO Neil F. McFarlane will present at the William Blair Growth Stock Conference on June 10, 2020, at 9:20 a.m. Central Time. The presentation will be available live on the company's investor relations website, with a replay accessible for 30 days post-event. Adamas focuses on innovative therapies for neurological diseases, highlighted by the FDA-approved GOCOVRI® (amantadine), the first treatment for dyskinesia in Parkinson's patients on levodopa therapy. For more details, visit www.adamaspharma.com.
Positive
- None.
Negative
- None.
News Market Reaction – ADMS
On the day this news was published, ADMS declined 2.22%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
EMERYVILLE, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a clinically meaningful difference to people affected by neurological diseases, today announced that Neil F. McFarlane, the Company’s Chief Executive Officer, is scheduled to present at the William Blair Growth Stock Conference on Wednesday, June 10 at 9:20 a.m. Central Time (7:20 a.m. Pacific Time).
The presentation will be webcast live from the investor relations section of the Adamas website at http://ir.adamaspharma.com/events-presentations. An archived version of the webcast will be available via replay for 30 days following the presentation.
About Adamas Pharmaceuticals, Inc.
At Adamas, our purpose and vision are clear: deliver innovative medicines that make a clinically meaningful difference for patients, caregivers and society. We are a fully-integrated company focused on growing a portfolio of therapies to address a range of neurological diseases. In 2018, Adamas successfully launched GOCOVRI® (amantadine) extended-release capsules, the first and only FDA-approved medicine for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. GOCOVRI is also the only medicine clinically proven to reduce both dyskinesia and OFF. For more information, please visit www.adamaspharma.com.
Contact:
Investors:
Peter Vozzo
Managing Director, Westwicke
443-213-0505
peter.vozzo@westwicke.com
Media:
Sarah Mathieson
Vice President of Corporate Communications
510-450-3528
smathieson@adamaspharma.com
FAQ
When is Neil F. McFarlane's presentation at the William Blair Growth Stock Conference?
Where can I watch the Adamas Pharmaceuticals presentation live?
What is GOCOVRI® and why is it significant?
How long will the webcast of the Adamas presentation be available for replay?
What is the stock symbol for Adamas Pharmaceuticals?
